Jump to navigation Jump to search
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass328.407 g/mol

Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.[1]

The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.[2] BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.[3] [4]

Experimental data indicate that peramivir may have useful activity against many viruses of interest, including H5N1 (avian bird flu) , hepatitis B, polio, measles and smallpox. Peramivir is active in a hamster model of yellow fever, a finding which is not surprising, given the familial relationship of yellow fever and hepatitis C viruses as flaviviridae. Peramivir is active against other important flaviviridae such as West Nile virus and dengue fever.Template:Facts


  1. "HHS Pursues Advance Development of New Influenza Antiviral Drug" (Press release). US Department of Health and Human Services. 2007-01-04. Retrieved 2007-05-25. Check date values in: |date= (help)
  2. Pollack, Andrew (2005-10-07). "Talk of Bird Flu Pandemic Revives Interest in Passed-Over Drugs". New York Times. Retrieved 2007-05-25. Check date values in: |date= (help)
  3. "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. Retrieved 2007-05-25. Check date values in: |date= (help)
  4. "Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. Retrieved 2007-05-25. Check date values in: |date= (help)

Influenza Microchapters


Patient Information


Historical Perspective




Differentiating Influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies


Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Peramivir On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Peramivir

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peramivir

CDC on Peramivir

Peramivir in the news

Blogs on Peramivir

Directions to Hospitals Treating Influenza

Risk calculators and risk factors for Peramivir

Template:WikiDoc Sources